Deals & IPOs

Shionogi closes $2 billion IntraBio deal, adds AQNEURSA

Shionogi closed its $2 billion IntraBio acquisition, gaining worldwide AQNEURSA rights, U.S. and European Niemann-Pick approvals, and a platform to expand rare-disease treatments.

By Nathan Brooks

4 min read

Shionogi Completes $2 Billion IntraBio Acquisition
Shionogi Completes $2 Billion IntraBio Acquisitionjarmoluk / pixabay

What's News

  • Shionogi completed its $2 billion acquisition of IntraBio.
  • The deal transfers worldwide AQNEURSA intellectual property and commercialization rights to Shionogi.
  • September 2026: The FDA approved AQNEURSA for ataxia in adults and children with Ataxia-Telangiectasia weighing at least 15 kilograms.
  • U.S. Niemann-Pick approval covers patients weighing at least 15 kilograms; European approval covers patients aged six and older weighing at least 20 kilograms.
  • AQNEURSA remains under European review for Ataxia-Telangiectasia and is in Phase 3 for CACNA1A-related disorders.

By Nathan Brooks

Shionogi has completed its $2 billion acquisition of IntraBio, adding the rare-disease treatment AQNEURSA and IntraBio’s development and commercialization capabilities to its global portfolio. Shionogi acquired all outstanding IntraBio shares through its New Jersey-based subsidiary. The transaction includes worldwide intellectual property and commercialization rights for AQNEURSA.

What does the deal change for Shionogi?

Shionogi said the acquisition strengthens its global organization with additional rare-disease expertise. The company will combine IntraBio’s development and commercialization capabilities with its own and continue the clinical programs IntraBio started. It also plans to examine AQNEURSA’s potential in additional rare diseases.

The transaction follows Shionogi’s acquisition of RADICAVA ORS, a treatment for amyotrophic lateral sclerosis. Shionogi said the additions have helped establish a commercial and medical-affairs foundation in rare and neurodegenerative diseases. Shionogi also lists clinical programs involving Pompe disease, Fragile X syndrome, Jordan’s syndrome, and other rare neurodegenerative conditions.

Isao Teshirogi, CEO of Shionogi, said:

“With the closing of the IntraBio acquisition, we welcome AQNEURSA to Shionogi’s growing portfolio and strengthen our global capabilities with additional rare disease expertise. For nearly 150 years, Shionogi has grown our business by adapting to the changing needs of patients.

This milestone is the latest representation of our steadfast commitment to deliver innovative medicines to protect the health and wellbeing of the patients we serve.”

AQNEURSA has approval in the United States and Europe for certain neurological manifestations of Niemann-Pick disease type C, according to Shionogi. The two authorizations differ on age and weight eligibility.

  • The U.S. approval covers adults and pediatric patients weighing at least 15 kilograms.
  • The European authorization covers adults and children aged six and older who weigh at least 20 kilograms, either with miglustat or as a standalone treatment when miglustat cannot be tolerated.

In September 2026, the U.S. Food and Drug Administration approved AQNEURSA as the first treatment targeting ataxia in adults and pediatric patients diagnosed with Ataxia-Telangiectasia who weigh at least 15 kilograms. The therapy is under European regulatory review for Ataxia-Telangiectasia. Shionogi is evaluating AQNEURSA in a Phase 3 study for CACNA1A-related disorders.

Nathan McCutcheon, President and CEO of Shionogi Inc., said:

“Through acquisitions, integrations and strategic hires, Shionogi is building a strong, sustainable rare disease presence with a clear purpose: to make a meaningful difference for patients. We have the infrastructure, portfolio, and commitment to deliver the medicines, patient support and services, and the scientific expertise and determination to advance new treatment options for tomorrow.”

Huw Tippett, CEO of Shionogi Europe, said:

“We look forward to partnering with patient groups representing people living with these devastating conditions, and learning from patients, families and carers about the challenges they face and how we can best help improve their lives.”

For Shionogi’s commercial and medical-affairs teams, the immediate gain is control: one owner now holds the AQNEURSA intellectual property and worldwide commercialization rights. The company also says it has patient support, services, and scientific expertise available to advance the asset.

Patient groups expect the transaction to matter most for access. Brad Margus, Founder of A-T Children’s Project, said:

“We look forward to partnering with the Shionogi team. The recent U.S. regulatory approval of AQNEURSA, the first targeted treatment for A-T, has brought hope to many children and their families. With the additional reach and resources that Shionogi brings, we are hopeful that more A-T families will be able to access this treatment.”

For the Niemann-Pick community, Heather Teal, Executive Director of the National Niemann-Pick Disease Foundation, said:

“For the Niemann-Pick community, this acquisition is an opportunity to build on progress to date for people living with NPC and their families. We are deeply grateful to IntraBio for securing approval for AQNEURSA and their support of our community.

We look forward to working with Shionogi to expand access and ensure this important therapy reaches the families who need it most.”

The deal gives Shionogi worldwide control of AQNEURSA, but the expansion case still depends on execution. The next proof points are a European regulatory decision for Ataxia-Telangiectasia, Phase 3 progress in CACNA1A-related disorders, and evidence that Shionogi can turn its added reach into broader access.

Source: pulse2.com

Share this article:

More from Nathan Brooks

Nathan Brooks

Show full bio

News editor covering regulation, policy and their impact on entrepreneurship, startups and venture funding at Business Bearings.

2,473 articles

Related articles

« Previous article